Identification of plumericin as a potent new inhibitor of the NF-κB pathway with anti-inflammatory activity in vitro and in vivo

British Journal of Pharmacology

Volumn 171, Issue 7, 2014, Pages 1676-1686

  Fakhrudin, N ^a,b   Waltenberger, B ^c   Cabaravdic, M ^d   Atanasov, A G ^a   Malainer, C ^a   Schachner, D ^a   Heiss, E H ^a   Liu, R ^a   Noha, S M ^c   Grzywacz, A M ^a   Mihaly Bison, J ^d   Awad, E M ^d   Schuster, D ^c   Breuss, J M ^d   Rollinger, J M ^c   Bochkov, V ^d   Stuppner, H ^c   Dirsch, V M ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b GADJAH MADA UNIVERSITY   (Indonesia)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

adhesion molecules; IKK ; inflammation; I B; natural products; NF B; peritonitis; plumericin

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIINFLAMMATORY AGENT; CYCLIC AMP; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FORSKOLIN; HIMATANTHUS SUCUUBA EXTRACT; I KAPPA B; I KAPPA B KINASE BETA; INTERCELLULAR ADHESION MOLECULE 1; LACTATE DEHYDROGENASE; LUCIFERASE; PLACEBO; PLANT EXTRACT; PLUMERICIN; THIOGLYCOLIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BARK; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG TARGETING; FLOW CYTOMETRY; GENETIC TRANSFECTION; HIMATANTHUS SUCUUBA; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MALE; MEDICINAL PLANT; MOUSE; MOUSE MODEL; NONHUMAN; PERITONITIS; PLANT STEM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING;

ADHESION MOLECULES; IKK-Β; INFLAMMATION; IΚB; NATURAL PRODUCTS; NF-ΚB; PERITONITIS; PLUMERICIN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOCYNACEAE; CELL ADHESION MOLECULES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; INDENES; INFLAMMATION; INFLAMMATION MEDIATORS; IRIDOIDS; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; PHOSPHORYLATION; PLANT EXTRACTS; SIGNAL TRANSDUCTION; THIOGLYCOLATES; TRANSFECTION;

EID: 84908895297     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12558     Document Type: Article

References (39)

1. Amaral AC, Silva JRD, Ferreira JL, Pinheiro ML, (2007). Monograph of Himatanthus sucuuba, a plant of Amazonian folk medicine. Pharmacogn Rev 1: 305-313.
2. Baumgartner RR, Steinmann D, Heiss EH, Atanasov AG, Ganzera M, Stuppner H, et al. (2010). Bioactivity-guided isolation of 1,2,3,4,6-penta-O-galloyl-D-glucopyranose from Paeonia lactiflora roots as a PTP1B inhibitor. J Nat Prod 73: 1578-1581.
3. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, et al. (2001). SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 98: 13681-13686.
4. Bork PM, Schmitz ML, Kuhnt M, Escher C, Heinrich M, (1997). Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappaB. FEBS Lett 402: 85-90.
5. Ehrich M, Sharova L, (2001). In vitro methods for detecting cytotoxicity. Curr Protoc Toxicol. Chapter 2: Unit 2 6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23045046 (accessed 19/2/2014).
6. Gamble C, McIntosh K, Scott R, Ho KH, Plevin R, Paul A, (2012). Inhibitory kappa B Kinases as targets for pharmacological regulation. Br J Pharmacol 165: 802-819.
7. Gerlo S, Kooijman R, Beck IM, Kolmus K, Spooren A, Haegeman G, (2011). Cyclic AMP: a selective modulator of NF-kappaB action. Cell Mol Life Sci 68: 3823-3841.
8. Graham FL, van der Eb AJ, (1973). A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52: 456-467.
9. Hayden MS, Ghosh S, (2004). Signaling to NF-kappaB. Genes Dev 18: 2195-2224.
10. Huang WC, Chan ST, Yang TL, Tzeng CC, Chen CC, (2004). Inhibition of ICAM-1 gene expression, monocyte adhesion and cancer cell invasion by targeting IKK complex: molecular and functional study of novel alpha-methylene-gamma-butyrolactone derivatives. Carcinogenesis 25: 1925-1934.
11. Huynh QK, Boddupalli H, Rouw SA, Koboldt CM, Hall T, Sommers C, et al. (2000). Characterization of the recombinant IKK1/IKK2 heterodimer. Mechanisms regulating kinase activity. J Biol Chem 275: 25883-25891.
12. Jin SL, Lan L, Zoudilova M, Conti M, (2005). Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 175: 1523-1531.
13. Karin M, Yamamoto Y, Wang QM, (2004). The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3: 17-26.
14. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
15. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM, (2001). The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 8: 759-766.
16. Lopez-Franco O, Hernandez-Vargas P, Ortiz-Munoz G, Sanjuan G, Suzuki Y, Ortega L, et al. (2006). Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 26: 1864-1870.
17. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
18. May MJ, Marienfeld RB, Ghosh S, (2002). Characterization of the Ikappa B-kinase NEMO binding domain. J Biol Chem 277: 45992-46000.
19. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, et al. (1997). IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 278: 860-866.
20. de Miranda AL, Silva JR, Rezende CM, Neves JS, Parrini SC, Pinheiro ML, et al. (2000). Anti-inflammatory and analgesic activities of the latex containing triterpenes from Himatanthus sucuuba. Planta Med 66: 284-286.
21. Nam NH, (2006). Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem 6: 945-951.
22. Newman DJ, Cragg GM, (2012). Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75: 311-335.
23. Noha SM, Atanasov AG, Schuster D, Markt P, Fakhrudin N, Heiss EH, et al. (2011). Discovery of a novel IKK-beta inhibitor by ligand-based virtual screening techniques. Bioorg Med Chem Lett 21: 577-583.
24. Perkins ND, (2007). Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8: 49-62.
25. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, et al. (1997). Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 272: 21096-21103.
26. Rahman A, Anwar KN, Minhajuddin M, Bijli KM, Javaid K, True AL, et al. (2004). cAMP targeting of p38 MAP kinase inhibits thrombin-induced NF-kappaB activation and ICAM-1 expression in endothelial cells. Am J Physiol Lung Cell Mol Physiol 287: L1017-L1024.
27. Rao RM, Yang L, Garcia-Cardena G, Luscinskas FW, (2007). Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res 101: 234-247.
28. Rozema E, Atanasov AG, Fakhrudin N, Singhuber J, Namduang U, Heiss EH, et al. (2012). Selected extracts of Chinese herbal medicines: their effect on NF-kappaB, PPARalpha and PPARgamma and the respective bioactive compounds. Evid Based Complement Alternat Med 2012: 983023. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22675394 (accessed 19/2/2014).
29. Saadane A, Masters S, DiDonato J, Li J, Berger M, (2007). Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice. Am J Respir Cell Mol Biol 36: 728-736.
30. Schiller HB, Szekeres A, Binder BR, Stockinger H, Leksa V, (2009). Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor. Mol Biol Cell 20: 745-756.
31. Sepp A, Binns RM, Lechler RI, (1996). Improved protocol for colorimetric detection of complement-mediated cytotoxicity based on the measurement of cytoplasmic lactate dehydrogenase activity. J Immunol Methods 196: 175-180.
32. Tabas I, Glass CK, (2013). Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339: 166-172.
33. Vogl S, Picker P, Mihaly-Bison J, Fakhrudin N, Atanasov AG, Heiss EH, et al. (2013). Ethnopharmacological in vitro studies on Austria's folk medicine-An unexplored lore in vitro anti-inflammatory activities of 71 Austrian traditional herbal drugs. J Ethnopharmacol 149: 750-771.
34. Waelchli R, Bollbuck B, Bruns C, Buhl T, Eder J, Feifel R, et al. (2006). Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK. Bioorg Med Chem Lett 16: 108-112.
35. Waltenberger B, Rollinger JM, Griesser UJ, Stuppner H, Gelbrich T, (2011). Plumeridoid C from the Amazonian traditional medicinal plant Himatanthus sucuuba. Acta Crystallogr C 67 (Pt 10): o409-o412.
36. Wang JG, Mahmud SA, Thompson JA, Geng JG, Key NS, Slungaard A, (2006). The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood 107: 558-565.
37. Weiss U, (2008). Inflammation. Nature 454: 427. Available at: http://www.nature.com/nature/journal/v454/n7203/full/454427a.html (accessed 19/2/2014).
38. Wood CA, Lee K, Vaisberg AJ, Kingston DG, Neto CC, Hammond GB, (2001). A bioactive spirolactone iridoid and triterpenoids from Himatanthus sucuuba. Chem Pharm Bull (Tokyo) 49: 1477-1478.
39. Yougbare I, Boire G, Roy M, Lugnier C, Rouseau E, (2013). NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-kappaB signalling pathways while reducing proinflammatory cytokine production. Can J Physiol Pharmacol 91: 353-361.